0 seconds of 2 minutes, 48 secondsVolume 0%
Press shift question mark to access a list of keyboard shortcuts
00:00
02:48
02:48
 
  • Psyence Group (PSYG) has provided an update on its  three strategic focus areas
  • Dr. Clive Ward-Able has been appointed as Medical Director, Head of Research & Development and Early Commercialization
  • ISO22000 certified commercial psilocybin production facility and lab upgraded
  • GOODMIND™, functional mushroom product, launched online and in-store
  • The company completed a C$1.273 million private placement

Psyence Group (PSYG) has provided an update on its  three strategic focus areas namely: Psyence Therapeutics, Psyence Production and Psyence Function.

Highlights:

  • Partnership with CRO Clerkenwell Health to design and deliver Psyence’s UK clinical trial progressing; exclusive licensing agreement with Filament Health
  • Dr. Clive Ward-Able has been appointed as Medical Director, Head of Research & Development and Early Commercialization for Psyence
  • ISO22000 certified commercial psilocybin production facility and lab upgraded
  • Received an import permit from Health Canada on behalf of Psilo Scientific
  • GOODMIND™, functional mushroom product, launched online and in-store, sale through 300 stores of one of Africa’s largest coffee retail chains
  • Previously announced C$1.273 million private placement being closed
  • Exploring capital market initiatives in UK, hires Investment Bank

Psyence CEO Dr. Neil Maresky, sat down with Coreena Robertson to discuss the update.

Psyence is a life science biotechnology company focused on natural psychedelics. Psyence works with natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care.

Psysence Group Inc. (PSYG) opened trading at C$0.085 per share.

More From The Market Online
AI generated stock image,

@ the Bell: Markets pop on copper price and geopolitical tensions

Canada’s main stock index increased on Tuesday, driven by geopolitical tensions and uncertainties surrounding tariffs, which boosted copper.
cannabis, weed

Navigating Canada’s cannabis market in the face of U.S. tariff concerns

Canada’s cannabis market has been evolving rapidly since legalization, presenting both opportunities and challenges for investors.
AI generated stock image Canadian Maple Leaf on top of stock market graph, with people on the floor looking upward

@ the Bell: TSX starts week strong

The TSX kicked off the week with a strong rally, reflecting gains seen on Wall Street as the US might adopt a moderate tariff…